September 29, 2015 | The Israeli biomedical firm Aposense and the leading international pharmaceutical company Pfizer announced that they would enter into a research agreement. The agreement will see to the technological evaluation of Aposense’s ML-10 molecule that is able to identify apoptosis, a process of programmed cell death. Aposense was founded in 1996 by Ilan Ziv and Yaacov Gotenstein.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts

Israeli AI Safety Tool Among TIME’S Best Inventions For 2024
October 31, 2024

TAU Team Discovers Mechanism To Eliminate Cancerous Tumors
October 30, 2024

Ashdod Port Investing In Startups As Part Of Innovation Strategy
October 29, 2024

BGU Develops Fast Fact Checking Via News Sources Not People
October 28, 2024
Facebook comments